Olaparib: New Standard for BRCA-Mutated Breast Cancer? - Medscape

Medscape

Olaparib: New Standard for BRCA-Mutated Breast Cancer? Medscape CHICAGO — A new option for women with BRCA-mutated breast cancer has emerged. The poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib (Lynparza, Astra Zeneca) significantly improved progression-free survival in women with ... Drug helps fight breast tumors tied to 'cancer genes'Medical Xpress AstraZeneca's Lynparza slows advanced breast cancer progression: studyReuters AstraZeneca's Lynparza Slows Spread of Inherited Breast CancerBloomberg Forbes -LWW Journals (blog) -Newswise (press release) -Financial Times all 31 news articles »

from Health - Google News http://ift.tt/2sH5m5X